Trial results for a Phase 1/Phase 2 study (NCT03459222) investigating immunotherapy combinations including nivolumab in participants with advanced cancer were posted on ClinicalTrials.gov on 2026-04-06. The study reported that most treatment arms showed zero or few participants with Grade 3/Grade 4 laboratory test results.

Background

This study investigated immunotherapy combinations for participants with advanced cancer. The interventions included relatlimab, nivolumab, BMS-986205, and ipilimumab.

Trial design

The study (NCT03459222) was a Phase 1/Phase 2 investigational study that enrolled 229 participants with advanced cancer. The trial aimed to assess the safety and preliminary activity of triple combinations, specifically relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab. These combinations were evaluated in both immunotherapy-naive and pretreated populations across select advanced tumor types.

Key results

The key results focused on the number of participants experiencing Grade 3/Grade 4 laboratory test results across various treatment arms:

What this means

The posted results indicate that the investigated immunotherapy combinations, including nivolumab, relatlimab, BMS-986205, and ipilimumab, generally demonstrated a favorable safety profile concerning severe laboratory abnormalities. Across most treatment arms, zero or very few participants experienced Grade 3 or Grade 4 laboratory test results, suggesting that these combinations may be manageable in terms of severe lab-related adverse events in participants with advanced cancer.

Source

The information for these trial results was sourced from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT03459222, titled "An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread," were posted on 2026-04-06 on clinicaltrials.gov.